Claims for Patent: 9,593,378

Summary for Patent: 9,593,378

Title:	BCR-ABL1 splice variants and uses thereof
Abstract:	The present invention is based on BCR-ABL1 splice variants which result from insertion and/or truncation of the bcr-abl1 transcript and the finding that these variants provide resistance to kinase domain inhibitors such as imatinib, nilotinib and dasatinib.
Inventor(s):	Ma; Wanlong (Aliso Viejo, CA)
Assignee:	QUEST DIAGNOSTICS INVESTEMENTS INCORPORATED (Wilmington, DE)
Application Number:	14/076,324
Patent Claims:	1. A method of detecting the presence of a nucleic acid encoding a 195-INS bcr-abl splice variant in a sample comprising bcr-abl nucleic acids, comprising contacting the sample with a labeled nucleic acid probe that hybridizes to the 5' junction site or the 3' junction site of the intron 4 insertion in the 195-INS bcr-abl splice variant and detecting the hybridized labeled nucleic acid probe to detect the bcr-abl splice variant. 2. The method of claim 1, wherein the sample is a biological sample obtained from a patient diagnosed with a myeloproliferative disease. 3. The method of claim 1, wherein the sample comprises blood cells. 4. The method of claim 3, wherein the sample comprises peripheral blood mononuclear cells (PBMCs). 5. The method of claim 1, wherein the sample comprises mRNA. 6. The method of claim 1, wherein the sample comprises cDNA. 7. The method of claim 1, wherein the labeled nucleic acid probe has a sequence selected from the group consisting of SEQ ID NOs: 11 and 12. 8. The method of claim 7, wherein the labeled nucleic acid probe hybridizes to mRNA in the sample. 9. The method of claim 7, wherein the labeled nucleic acid probe hybridizes to cDNA in the sample. 10. The method of claim 1, wherein the detection assay comprises amplifying at least a portion of a nucleic acid encoding the 195-INS bcr-abl splice variant. 11. The method of claim 10, wherein said amplifying comprises performing polymerase chain reaction with primers directed to a nucleic acid sequence encoding the 195-INS bcr-abl splice variant.

Details for Patent 9,593,378

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26